GlaxoSmithKline (NYSE:GSK) dermatology and skin subsidiary Stiefel has submitted to regulators a new drug application for tazarotene foam, an acne skin care treatment product. If approved by the U.S.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈